2,271 press releases in English indexed under biotech & pharma.
SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No.
SAN CARLOS, Calif., Sept. 28, 2026 -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.
NEW YORK, September 28, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of Septembe
CHICAGO, September 28, 2026--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced that the U.S. Food and Drug Administration ("FDA") has approved a high-concentration formulation ("HCF") for YUSIMRY® (adalimumab-aqvh), as an interchangeable biosimilar to Humira®.
Lille (France), Cambridge (Massachusetts, United States); September 28, 2026 – GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2026 financial results and provided a corporate update.
Swiss longevity skincare brand reveals new clinical data supporting a new approach to skin health, biological aging and skinspan NEW YORK, Sept. 28, 2026 -- INSTYTUTUM, the Swiss longevity skincare brand founded by longevity scientist and biotech innovator Dr. Natalia Bobok,...
NEW YORK, Sept. 28, 2026 -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential...
Company announcement No. 50 / 2026
NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.
Oncolytics announced continued clinical and operational progress for the REO 033 program evaluating pelareorep in second-line RAS-mutant mCRC.
U.S. Pediatric Clinical Trials Market to Reach USD 11.82 Billion and Europe USD 10.13 Billion by 2035 as Regulatory Incentives, Pediatric Drug Pipelines, and Decentralized Trial Models Accelerate Research Activity. U.S. Pediatric Clinical Trials Market to Reach USD 11.82 Billion and Europe USD 10.13 Billion by 2035 as Regulatory Incentives, Pediatric Drug Pipelines, and Decentralized Trial Models Accelerate Research Activity.
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only...